SCHEMBL3352032

SCHEMBL3352032

CCCc1cccc(C(N)=O)c1CCC

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 4/20 0.41
KMT2A Q03164 3/20 0.41
LMNA P02545 2/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 2/20 0.41
NR1I2 O75469 1/20 0.41
CHRM2 P08172 1/20 0.41
CYP3A4 P08684 1/20 0.41
ADRA2A P08913 1/20 0.41
OPRK1 P41145 1/20 0.41
HTR2B P41595 1/20 0.41
SLC6A3 Q01959 1/20 0.41
HDAC6 Q9UBN7 1/20 0.41
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 3/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
HTT P42858 1/20 0.39
PARP2 Q9UGN5 1/20 0.39
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Charcoal, Activated SCHEMBL9341326 0.98 PARP1 (0.40) PARP1KMT2ALMNAMAPTMEN1
SCHEMBL6314578 0.98 PARP1 (0.40) PARP1KMT2ALMNAMAPTMEN1
Oxalic Acid SCHEMBL27731733 0.95 HMGB1 (0.38) PARP1KMT2ALMNAMAPTMEN1
SCHEMBL144959 0.93 PARP1 (0.44) PARP1KMT2ALMNAMAPTMEN1
SCHEMBL2964481 0.89 PARP1 (0.45) PARP1KMT2ALMNAMAPTMEN1
SCHEMBL6285466 0.86 CYP3A4 (0.45) PARP1KMT2ALMNAMAPTMEN1
SCHEMBL22736732 0.85 BID (0.48) KMT2ALMNAMAPTMEN1NR1I2
Charcoal, Activated SCHEMBL9345982 0.85 CYP3A4 (0.44) PARP1KMT2ALMNAMAPTMEN1
SCHEMBL5486335 0.84 KMT2A (0.43) KMT2ALMNAMAPTMEN1NR1I2
SCHEMBL8878547 0.84 LTB4R (0.44) KDM4EALDH1A1HPGDLTB4RLTB4R2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101084235-A 3-deoxyglucosone and skin DYNAMIS THERAPEUTICS INC (US) 2007-12-05 CN claimed
CN-1882544-A Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer s disease MERCK & CO INC (US) 2006-12-20 CN claimed
CN-1759095-A N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARM INC (US) 2006-04-12 CN claimed
EP-1542964-A2 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2005-06-22 EP claimed
WO-2004058686-A1 HYDROXYPROPYL AMIDES FOR THE TREATMENT OF ALZHEIMER’S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2004-07-15 WO claimed
WO-2004029019-A2 COMPOUNDS FOR THE TREATMENT OF ALZHEIMER’S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2004-04-08 WO claimed
WO-2003047572-A1 USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS MERCK PATENT GMBH (DE) 2003-06-12 WO claimed
CN-117229257-A Meta-sulfamoyl benzamide compound and preparation method, pharmaceutical composition and application thereof 中国药科大学 2023-12-15 CN disclosed
CN-109286041-B Electrolyte and secondary lithium battery 宁德时代新能源科技股份有限公司 2020-12-11 CN disclosed
US-9688618-B2 Hydroxamic acids and uses thereof HAWAII BIOTECH, INC. (US) 2017-06-27 US disclosed
US-20170036996-A1 HYDROXAMIC ACIDS AND USES THEREOF HAWAII BIOTECH, INC. 2017-02-09 US disclosed
CN-105601551-A Sulfur-containing hindered phenolic compound as well as preparation and application thereof CHINA PETROLEUM & CHEM CORP 2016-05-25 CN disclosed
CN-102365280-B adenosine receptor ligands and uses thereof DOMAIN THERAPEUTICS (FR) 2014-10-29 CN disclosed
WO-2002048122-A2 BENZAMIDINE DERIVATIVES ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) 2002-06-20 WO disclosed
CN-1089944-A The N-Benzanilide derivatives GLAXO GROUP LTD (GB) 1994-07-27 CN disclosed
US-5306312-A Dyeing fabric by heating in solution containing dye and aliphatic amide dye diffusion promoter BURLINGTON INDUSTRIES, INC. (US) 1994-04-26 US disclosed
CN-1071922-A The N-Benzanilide derivatives GLAXO GROUP LTD (GB) 1993-05-12 CN disclosed
CN-1016246-B Process for preparing aminophenol derivatives GLAXO GROUP LTD (GB) 1992-04-15 CN disclosed
EP-0178919-B1 AMINOPHENOL DERIVATIVES GLAXO GROUP LIMITED (GB) 1988-12-21 EP disclosed
CN-86102681-A The preparation method of p-aminophenol derivative and purposes 1987-10-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170036996-A1 HYDROXAMIC ACIDS AND USES THEREOF HRH3, H1-3, H1-0 PARP1 855/4885KMT2A 897/4885LMNA 1274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.